| Primary |
| Drug Use For Unknown Indication |
27.0% |
| Rheumatoid Arthritis |
20.6% |
| Systemic Lupus Erythematosus |
9.5% |
| Pain |
5.6% |
| Borrelia Burgdorferi Serology Positive |
4.8% |
| Crest Syndrome |
4.0% |
| Hypertension |
4.0% |
| Factor V Leiden Mutation |
3.2% |
| Polyarthritis |
2.4% |
| Prophylaxis |
2.4% |
| Sjogren's Syndrome |
2.4% |
| Thrombosis |
2.4% |
| Collagen Disorder |
1.6% |
| Gastritis |
1.6% |
| Lichen Planus |
1.6% |
| Migraine |
1.6% |
| Osteoporosis Prophylaxis |
1.6% |
| Prophylaxis Of Neural Tube Defect |
1.6% |
| Systemic Lupus Erythematosus Rash |
1.6% |
| Arthritis |
0.8% |
|
| Rash Generalised |
10.0% |
| Retinal Detachment |
10.0% |
| Bipolar I Disorder |
7.5% |
| Myasthenia Gravis |
7.5% |
| Sensory Disturbance |
7.5% |
| Acute Myocardial Infarction |
5.0% |
| Atrioventricular Block |
5.0% |
| Atrioventricular Block First Degree |
5.0% |
| Gastric Mucosal Lesion |
5.0% |
| Hyponatraemia |
5.0% |
| Left Ventricular Dysfunction |
5.0% |
| Sinus Bradycardia |
5.0% |
| Thrombocytopenia |
5.0% |
| Acne |
2.5% |
| Atrial Fibrillation |
2.5% |
| Atrial Tachycardia |
2.5% |
| Autoimmune Hepatitis |
2.5% |
| Electrolyte Imbalance |
2.5% |
| Headache |
2.5% |
| Induration |
2.5% |
|
| Secondary |
| Systemic Lupus Erythematosus |
25.6% |
| Rheumatoid Arthritis |
11.6% |
| Pain |
10.7% |
| Hypertension |
6.6% |
| Nephrotic Syndrome |
6.6% |
| Drug Use For Unknown Indication |
5.0% |
| Hypercholesterolaemia |
4.1% |
| Vena Cava Thrombosis |
4.1% |
| Abortion Induced |
3.3% |
| Gastritis Prophylaxis |
3.3% |
| Product Used For Unknown Indication |
3.3% |
| Asthma |
2.5% |
| Pulmonary Embolism |
2.5% |
| Glomerulonephritis Membranous |
1.7% |
| Induced Abortion |
1.7% |
| Inferior Venacaval Thrombosis |
1.7% |
| Lyme Borreliosis |
1.7% |
| Lyme Disease |
1.7% |
| Nephrotic Syndrome With Lesion Of Membranous Glomerulonephritis |
1.7% |
| Arthritis |
0.8% |
|
| Ventricular Septal Defect |
20.0% |
| Enanthema |
8.0% |
| Oxygen Saturation Decreased |
8.0% |
| Transaminases Increased |
8.0% |
| Urinary Tract Infection Bacterial |
8.0% |
| Acute Generalised Exanthematous Pustulosis |
4.0% |
| Atrial Tachycardia |
4.0% |
| Atrioventricular Block First Degree |
4.0% |
| Autoimmune Hepatitis |
4.0% |
| Gamma-glutamyltransferase Increased |
4.0% |
| Oedema |
4.0% |
| Paronychia |
4.0% |
| Rheumatoid Arthritis |
4.0% |
| Skin Discolouration |
4.0% |
| Skin Reaction |
4.0% |
| Thrombocytopenia |
4.0% |
| Vision Blurred |
4.0% |
|
| Concomitant |
| Rheumatoid Arthritis |
45.8% |
| Product Used For Unknown Indication |
19.1% |
| Systemic Lupus Erythematosus |
9.4% |
| Drug Use For Unknown Indication |
7.3% |
| Hypertension |
3.1% |
| Osteoporosis |
3.1% |
| Pain |
2.4% |
| Arthritis |
1.7% |
| Ankylosing Spondylitis |
1.4% |
| Hypothyroidism |
0.9% |
| Mental Disorder |
0.9% |
| Diabetes Mellitus |
0.7% |
| Hepatitis C |
0.7% |
| Ovarian Cancer |
0.7% |
| Blood Follicle Stimulating Hormone Decreased |
0.5% |
| Blood Luteinising Hormone Decreased |
0.5% |
| Breast Cancer |
0.5% |
| Epilepsy |
0.5% |
| Haemodialysis |
0.5% |
| Hepatic Neoplasm Malignant |
0.5% |
|
| Systemic Lupus Erythematosus |
14.0% |
| Thrombocytopenia |
10.5% |
| Sinusitis |
8.8% |
| Cutaneous Lupus Erythematosus |
7.0% |
| Death |
5.3% |
| Skin Ulcer |
5.3% |
| Weight Decreased |
5.3% |
| Biliary Tract Disorder |
3.5% |
| Bronchial Carcinoma |
3.5% |
| Cardiac Failure |
3.5% |
| Gastroenteritis |
3.5% |
| Oedema |
3.5% |
| Plasmacytoma |
3.5% |
| Pneumonia |
3.5% |
| Rheumatoid Arthritis |
3.5% |
| Thrombosis |
3.5% |
| Tremor |
3.5% |
| Tuberculosis |
3.5% |
| Vulvar Dysplasia |
3.5% |
| Angiotensin Converting Enzyme Increased |
1.8% |
|
| Interacting |
| Mixed Connective Tissue Disease |
25.0% |
| Change Of Bowel Habit |
12.5% |
| Musculoskeletal Pain |
12.5% |
| Osteoporosis Prophylaxis |
12.5% |
| Pain |
12.5% |
| Palpitations |
12.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
12.5% |
|
|
